Exenatide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Exenatide: From Type 2 Diabetes Mellitus to Primary Hereditary Glaucoma
One-Sentence Summary
Exenatide (DB01276) is a GLP-1 receptor agonist originally developed for type 2 diabetes mellitus. The TxGNN model predicts it may be effective for Primary Hereditary Glaucoma, but this pairing currently has no supporting clinical trials or published literature — the signal is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 Diabetes Mellitus (based on known pharmacology; not present in the supplied regulatory record) |
| Predicted New Indication | Primary Hereditary Glaucoma |
| TxGNN Prediction Score | 96.21% |
| Evidence Level | L5 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this candidate. Based on known information, Exenatide is a GLP-1 receptor agonist (incretin mimetic), and its efficacy in type 2 diabetes mellitus is well established through its effects on insulin secretion and glucose metabolism.
The link between a GLP-1 agonist and primary hereditary glaucoma is not obvious pharmacologically, and the evidence pack contains no clinical trials, ICTRP records, or literature connecting exenatide to this specific disease (rank 29,062 out of the full TxGNN candidate list). The high TxGNN score therefore reflects a graph-based similarity signal rather than any observed or mechanistically documented effect, and should be treated as a hypothesis-generating result only, not a validated pharmacological rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has no clinical trial or literature support, no available mechanism-of-action data, and the drug is not currently marketed in the EU dataset provided — the prediction rests solely on the TxGNN model score (Evidence Level L5).
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data from DrugBank or primary literature
- Preclinical/mechanistic evidence linking GLP-1 receptor activity to intraocular pressure or glaucoma pathophysiology
- TFDA/EMA label warnings and contraindications (currently a Blocking data gap per meta.data_gaps DG001)
- Confirmation of EU marketing status and any existing ophthalmic-relevant safety signals before any further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.